The invention comprises a process for the preparation of GalNAc oligonucleotide conjugates which comprises the coupling of a GalNAc cluster compound of the formula ##STR00001##
or corresponding salts, enantiomers and/or a stereoisomer thereof, with an oligonucleotide in the presence of an O-dicarboximidouronium salt as coupling agent.

The invention relates to a method for synthesising macromolecules made up of units U that are mostly monosaccharides or monosaccharide derivatives, by successive elongation of a first unit U1 attached by a covalent bond to an anchor molecule soluble in organic solvents. The elongation takes place by coupling with a monomer or oligomer M having at least two functions. The method is characterised in that the anchor molecule comprises a polyolefin chain or a polyolefin oligomer or a polyalkene, with at least 5 monomer units, and preferably between 10 and 50 monomer units, the polyolefin chain preferably being a polyisobutene chain.

The invention relates to a method for synthesising macromolecules made up of units U that are mostly monosaccharides or monosaccharide derivatives, by successive elongation of a first unit U1 attached by a covalent bond to an anchor molecule soluble in organic solvents. The elongation takes place by coupling with a monomer or oligomer M having at least two functions. The method is characterised in that the anchor molecule comprises a polyolefin chain or a polyolefin oligomer or a polyalkene, with at least 5 monomer units, and preferably between 10 and 50 monomer units, the polyolefin chain preferably being a polyisobutene chain.

Provided is a method for liberating sugar chains from a glycoprotein, including: a step of brining a reaction solution which contains hydroxylamines (a) and a basic reagent (b) into contact with the glycoprotein to obtain a mixed solution of sugar chains liberated from the glycoprotein and the reaction solution.

Provided is a method for liberating sugar chains from a glycoprotein, including: a step of brining a reaction solution which contains hydroxylamines (a) and a basic reagent (b) into contact with the glycoprotein to obtain a mixed solution of sugar chains liberated from the glycoprotein and the reaction solution.

The invention relates to a low molecular weight sulfate chondroitin and a preparation method thereof. A low molecular weight chondroitin sulfate with the average molecular weight of less than 1000 Dalton can be obtained by a production process of chondroitin sulfate lyase degradation, deproteinization, filtration and sterilization and drying using macromolecular sulfate chondroitin as a raw material. The low molecular weight Chondroitin sulfate has a narrow molecular weight distribution range, the ratio of chondroitin sulfate disaccharide is 43˜60% and the ratio of chondroitin sulfate tetrasaccharide is 30˜45%, the sum of chondroitin sulfate disaccharide and chondroitin sulfate tetrasaccharide is more than 87%, the total oligosaccharide content of low molecular weight chondroitin sulfate is more than 97% and the protein content is less than 0.5%; Compared with the general market macromolecule chondroitin sulfate, the product has more remarkable repair effect at the concentration of 50˜100 μg/mL on chondrocytes damaged by 1 mM hydrogen peroxide, with strong repair ability and repair rate of 14%˜23%. The low molecular weight chondroitin sulfate can be used to treat joint injury and is an important raw material for medical products, health care products, cosmetics and food.

The invention relates to a low molecular weight sulfate chondroitin and a preparation method thereof. A low molecular weight chondroitin sulfate with the average molecular weight of less than 1000 Dalton can be obtained by a production process of chondroitin sulfate lyase degradation, deproteinization, filtration and sterilization and drying using macromolecular sulfate chondroitin as a raw material. The low molecular weight Chondroitin sulfate has a narrow molecular weight distribution range, the ratio of chondroitin sulfate disaccharide is 43˜60% and the ratio of chondroitin sulfate tetrasaccharide is 30˜45%, the sum of chondroitin sulfate disaccharide and chondroitin sulfate tetrasaccharide is more than 87%, the total oligosaccharide content of low molecular weight chondroitin sulfate is more than 97% and the protein content is less than 0.5%; Compared with the general market macromolecule chondroitin sulfate, the product has more remarkable repair effect at the concentration of 50˜100 μg/mL on chondrocytes damaged by 1 mM hydrogen peroxide, with strong repair ability and repair rate of 14%˜23%. The low molecular weight chondroitin sulfate can be used to treat joint injury and is an important raw material for medical products, health care products, cosmetics and food.

The present invention provides a mannose-based mRNA targeted delivery system and use thereof. The mRNA can encode one or more target polypeptides and contains at least one mannose modification. The technical solution of the present invention modifies the mRNA molecule with a mannose, so that the mRNA can be directly and efficiently coupled with the mannose, and the targeted delivery of the mRNA is realized without the need for a carrier.

There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.

There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.